Abstract
Sorafenib, a new antiangiogenic and antiproliferative agent, is currently used for hepatocellular and renal cell carcinoma. We report here the case of a patient with two cancers, a locally advanced cancer of the piriform sinus and a hepatocellular carcinoma, who was given sorafenib. Tumor response of both cancers might suggest that sorafenib could be effective against head and neck cancer.
MeSH terms
-
Benzenesulfonates / therapeutic use*
-
Carcinoma, Hepatocellular / complications
-
Carcinoma, Hepatocellular / diagnosis
-
Carcinoma, Hepatocellular / drug therapy*
-
Head and Neck Neoplasms / complications
-
Head and Neck Neoplasms / diagnosis
-
Head and Neck Neoplasms / drug therapy*
-
Humans
-
Liver Neoplasms / complications
-
Liver Neoplasms / diagnosis
-
Liver Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Neoplasm Metastasis / diagnosis
-
Neoplasm Metastasis / drug therapy
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Portal Vein / pathology*
-
Pyridines / therapeutic use*
-
Sorafenib
-
Treatment Outcome
-
Venous Thrombosis / complications
-
Venous Thrombosis / diagnosis
-
Venous Thrombosis / drug therapy*
Substances
-
Benzenesulfonates
-
Phenylurea Compounds
-
Pyridines
-
Niacinamide
-
Sorafenib